| Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing drug candidates for immuno-inflammatory diseases. Co.'s pipeline of drug candidates that Co. is developing includes: ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; and ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, for the treatment of moderate to severe atopic dermatitis. Co. is also developing ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, as a potential treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. We show 25 historical shares outstanding datapoints in our ACRS shares outstanding history coverage, used to compute ACRS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACRS market cap history over the course of time is important for investors
interested in comparing ACRS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACRS versus a peer is one thing; comparing
ACRS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACRS can fluctuate over the course of history.
With this page we aim to empower investors researching ACRS by allowing them to research the ACRS market cap history.